The MOLOGEN AG Supervisory Board

 

Oliver Krautscheid
Chairman of the Supervisory Board

Member since: End of Annual General Meeting 2014
Appointed until: End of Annual General Meeting 2020
Function: Chairman of the Supervisory Board of MOLOGEN AG
Supervisory Board Positions: EASY SOFTWARE AG, Mülheim an der Ruhr (Chairman of the
Supervisory Board); listed in the General Standard of
Frankfurt Stock Exchange CD Deutsche Eigenheim AG,
Berlin (Chairman of the Supervisory Board); EPG Engineered
nanoProducts Germany AG, Griesheim (Chairman of the Supervisory Board)
Nationality: German

Short CV 

Oliver Krautscheid (born 1968) has been a member of multiple supervisory boards, a financial expert and management consultant for more than 19 years. Since 2014 he is the Chairman of the Supervisory Board of MOLOGEN AG.

He is currently a partner with Value Investor Partners GbR in Frankfurt, a family investment office co-founded by him, as well as CEO and president of the board of directors of The Fantastic Company AG, which has its head office in Switzerland.

He previously worked for various international consulting and auditing companies in Germany and in London including: Arthur Andersen, McKinsey & Co. and KPMG. At the latter, he worked as a partner in the area of Financial Advisory Services until 2004 and managed the "Strategic & Commercial Intelligence" business unit co-founded by him.

Mr. Krautscheid has advised on M&A transactions for major pharmaceutical companies and for biotech and venture capital. He graduated from the University of Cologne with a degree in business administration.

 

Dr. med. Stefan M. Manth
Vice Chairman of the Supervisory Board

Member since: End of Annual General Meeting 2014
Appointed until: End of Annual General Meeting 2019
Function: Vice Chairman of the Supervisory Board of MOLOGEN AG
Supervisory Board Positions: Dr Manth has been involved with various supervisory
bodies in Germany and abroad for more than 20 years.
Nationality: German

Short CV

Dr Manth (born 1956) is a physician with additional training in business (MBA from INSEAD) and has been working since the 1980s for the pharmaceutical and biotech industries. He spent 20 years working for the Roche Group (Roche Pharma and Chugai). Since 2014 he functions as Vice Chairman of the Supervisory Board of MOLOGEN AG.

His extensive management experience includes areas such as product development, clinical research, marketing and distribution of prescription and prescription-free drugs, organizational and personnel development, corporate, product and group strategy, corporate management, acquisition and integration, turn-around and change management.

He particularly distinguished himself, by establishing and developing the oncology business of the Roche Group, by far the current global leader in this therapeutic area.

 

 

Michael Schultz, Ph.D.
Member of the Supervisory Board

Member since:                        End of Annual General meeting 2018
Appointed until: End of Annual General Meeting 2023
Function: Member of the Supervisory Board of MOLOGEN AG
Supervisory Board Positions: Currently no
Nationality: German

Short CV

Michael Schultz is a diploma chemist. After his studies in Hamburg, Germany and at Georgetown University, Washington, D.C., US, he started his career in the Research Department of former Boehringer Mannheim in 1987 followed by assignments in the global Research Management at Roche in Basel, Switzerland, as President & Chief Scientific Officer at ChemBridge Research Labs, San Diego, CA, US and from 2003 on in the Research Management of Bayer HealthCare Pharma. From 2005 until 2013 Michael Schultz, Ph.D.,
held a leading position in the Business Development and Licensing Department at Bayer HealthCare. 

His professional experience includes in particular research and development of new pharmaceuticals, introduction of new medical devices and technologies, assessment and due diligence of biotech companies, in- and out-licensing of clinical development projects, project and portfolio management as well as integration and alliance management. 

Since 2014 Michael Schultz, Ph.D., is an independent consultant & coach to the biotech industry.